Vasomune Therapeutics, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.vasomune.com
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
Phase 2
Recruiting
- Conditions
- Acute Respiratory Distress SyndromeViral or Bacterial InfectionsPneumoniaCOVID-19 Acute Respiratory Distress SyndromePneumonia, ViralRespiratory Infection
- Interventions
- Drug: AV-001 InjectionDrug: AV-001 Placebo Injection
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Vasomune Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05123755
- Locations
- 🇺🇸
University of Florida College of Medicine, Jacksonville, Jacksonville, Florida, United States
🇺🇸Denver Health Medical Center, Denver, Colorado, United States
🇺🇸MedStar Health Research Institute, Inc., Hyattsville, Maryland, United States
A First-in-Human Study of AV-001 in Healthy Subjects
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Vasomune Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04737486
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath